.png "Xtant Medical Holdings (NYSE MKT: XTNT)")
In a report released today, Anthony Vendetti from Maxim Group maintained a Buy rating on Xtant Medical Holdings (NYSE MKT: XTNT), with a price target of $10. The company’s shares opened today at $5.87.
Vendetti wrote:
“Market close, XTNT reported relatively inline 2Q18 results, with GAAP EPS below expectations, primarily due to $1.2M of restructuring expenses. Revenue declined due to weakness in fixation sales, as well as the elimination of unprofitable business, but drove y/y gross margin expansion and operating expense declines.”
According to TipRanks.com, Vendetti is a 4-star analyst with an average return of 9.5% and a 53.7% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Ellex Medical Lasers Limited, Restoration Robotics Inc, and Milestone Scientific.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Xtant Medical Holdings with a $10 average price target.
See today’s analyst top recommended stocks >>
Based on Xtant Medical Holdings’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $5.25 million. In comparison, last year the company had a GAAP net loss of $9.69 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Xtant Medical Holdings, Inc. operates as a holding company, which supplies orthopedic and spine surgery products. The firm operates through its subsidiaries, Bacterin International, Inc. and X-spine Systems, Inc. Bacterin International develops, manufactures, and markets biologics products to domestic and international markets.
